We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CCOLA:BISTCoca-Cola Icecek A.S. Analysis

Data as of 2026-07-17 - not real-time

TRY 87.95

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Coca‑Cola Içecek trades at TRY 87.95, just above its DCF‑derived fair value of ~86, placing it in a *fairly valued* range. The 20‑day SMA (82.58) and 50‑day SMA (81.96) sit well below the current price, while the 200‑day SMA (68.49) is far lower, underscoring a sustained bullish bias. Technical momentum is supportive: the MACD line sits above its signal (bullish) and the RSI hovers around 60, indicating room for upside without immediate overbought pressure. Volume has been stable, and the stock enjoys a very low beta (~0.15), suggesting limited market‑wide volatility. On the fundamentals side, revenue grew 10.7% YoY to TRY 192 bn, margins remain healthy (gross ~36%, operating ~13%), and free cash flow exceeds TRY 13 bn, comfortably covering the modest 17% payout ratio. The dividend yield of 1.7% is well‑backed by strong operating cash flow, making the dividend sustainable. Analyst consensus is strongly positive (12 analysts, “strong_buy”) with a mean target of TRY 103, implying ~17% upside from current levels. The company’s defensive consumer‑staples positioning, diversified geography, and robust brand franchise add a layer of resilience. However, exposure to emerging markets and the Turkish lira introduces moderate currency and geopolitical risk. Overall, the blend of bullish technicals, solid cash generation, and attractive valuation makes CCOLA a compelling candidate for investors seeking stable growth and dividend income.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD and SMA alignment
  • Price near short‑term resistance at ~90
  • Stable volume and low beta

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 10% revenue growth and expanding margins
  • Attractive dividend yield with low payout ratio
  • Analyst consensus strong‑buy and ~17% upside potential

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Iconic brand franchise and defensive consumer‑defensive sector
  • Consistently strong cash flow supporting dividend sustainability
  • Low market beta and solid ROE (~22%) indicating resilient earnings

Key Metrics & Analysis

Financial Health

Revenue Growth10.70%
Profit Margin9.18%
P/E Ratio14.0
ROE21.99%
ROA9.22%
Debt/Equity54.13
P/B Ratio2.9
Op. Cash FlowTRY35.5B
Free Cash FlowTRY13.1B

Technical Analysis

TrendBullish
RSI59.9
SupportTRY 76.50
ResistanceTRY 90.20
MA 20TRY 82.58
MA 50TRY 81.96
MA 200TRY 68.49
MACDBullish
VolumeStable
Fear & Greed Index88.7

Valuation

Fair ValueTRY 86.12
Target PriceTRY 103.03
Upside/Downside17.15%
GradeFair
TypeBlend
Dividend Yield1.70%

Risk Assessment

Beta0.15
Volatility40.68%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.